Abbott Laboratories $ABT Shares Bought by Capital Research Global Investors

Capital Research Global Investors raised its position in Abbott Laboratories (NYSE:ABT) by 1.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 39,169,239 shares of the healthcare product maker’s stock after buying an additional 400,400 shares during the quarter. Abbott Laboratories comprises about 0.9% of Capital Research Global Investors’ holdings, making the stock its 23rd largest position. Capital Research Global Investors’ holdings in Abbott Laboratories were worth $4,907,523,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $25,000. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $27,000. Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at $33,000. Leonteq Securities AG purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $35,000. Finally, Turning Point Benefit Group Inc. purchased a new stake in shares of Abbott Laboratories during the 3rd quarter worth $39,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABT shares. Leerink Partners decreased their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Sanford C. Bernstein decreased their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, April 24th. Piper Sandler decreased their target price on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Finally, Daiwa Securities Group lowered shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research report on Wednesday, April 22nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.09.

Abbott Laboratories Price Performance

Abbott Laboratories stock opened at $91.20 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm’s 50-day simple moving average is $92.80 and its 200 day simple moving average is $109.31. The firm has a market capitalization of $158.85 billion, a PE ratio of 25.55, a P/E/G ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the firm earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.